Viridian Therapeutics, Inc.\DE SEC filings VRDN
Viridian Therapeutics, Inc.\DE has 817 filings in SEC EDGAR's recent list, going back to Nov 12, 2013. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 4 | Insider transaction | Aug 20, 2026 | Aug 19, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 20, 2026 | — |
| 144 | Notice of proposed sale | Aug 19, 2026 | — |
| 4 | Insider transaction | Aug 18, 2026 | Aug 14, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2026 | — |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 29, 2026 | Jun 26, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 26, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Agreement ended
|
May 28, 2026 | May 27, 2026 |
| 8-K |
Current report
Material agreement
|
May 26, 2026 | May 24, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| 4 | Insider transaction | May 13, 2026 | May 11, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 13, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Other events
|
May 11, 2026 | May 6, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 8, 2026 | — |
| 424B5 | Prospectus supplement | May 8, 2026 | — |
| 424B5 | Prospectus supplement | May 8, 2026 | — |
| FWP | Free writing prospectus | May 7, 2026 | — |
| FWP | Free writing prospectus | May 7, 2026 | — |
| 305B2 | Filing | May 7, 2026 | — |
| 424B5 | Prospectus supplement | May 6, 2026 | — |
| 424B5 | Prospectus supplement | May 6, 2026 | — |
| FWP | Free writing prospectus | May 5, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 5, 2026 | May 5, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| ARS | Annual report to shareholders | Apr 17, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 30, 2026 | Mar 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 27, 2026 | — |
| 4/A | Filing | Mar 9, 2026 | Mar 3, 2026 |
| 4/A | Filing | Mar 9, 2026 | Mar 3, 2026 |
| 4/A | Filing | Mar 9, 2026 | Mar 3, 2026 |
| 4/A | Filing | Mar 9, 2026 | Mar 3, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4/A | Filing | Mar 4, 2026 | Mar 3, 2025 |
| 4/A | Filing | Mar 4, 2026 | Mar 3, 2025 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Mar 2, 2026 |
| 144 | Notice of proposed sale | Mar 4, 2026 | — |
| 144 | Notice of proposed sale | Mar 4, 2026 | — |
| 144 | Notice of proposed sale | Mar 4, 2026 | — |
| 144 | Notice of proposed sale | Mar 4, 2026 | — |
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| 10-K | Annual report | Feb 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Jan 2, 2026 | Dec 31, 2025 |
| 144 | Notice of proposed sale | Dec 31, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 27, 2025 | — |
| 4 | Insider transaction | Oct 27, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 23, 2025 | Oct 21, 2025 |
| 424B5 | Prospectus supplement | Oct 23, 2025 | — |
| 424B5 | Prospectus supplement | Oct 21, 2025 | — |
| 8-K |
Current report
Results of operations
|
Oct 21, 2025 | Oct 21, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 20, 2025 | Oct 17, 2025 |
| S-3ASR | Automatic shelf registration | Sep 5, 2025 | — |
| S-8 | Employee stock plan registration | Aug 6, 2025 | — |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 30, 2025 | Jul 30, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 24, 2025 | Jun 20, 2025 |
| 4 | Insider transaction | Jun 11, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 20, 2025 | May 20, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 20, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 11, 2025 | — |
| 4 | Insider transaction | Apr 9, 2025 | Apr 7, 2025 |
| 3 | Initial insider ownership | Apr 9, 2025 | Apr 7, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 7, 2025 | Apr 2, 2025 |
| 4 | Insider transaction | Mar 12, 2025 | Mar 10, 2025 |
| 3 | Initial insider ownership | Mar 12, 2025 | Mar 10, 2025 |
| 4 | Insider transaction | Mar 12, 2025 | Mar 10, 2025 |
| 3 | Initial insider ownership | Mar 12, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 10, 2025 | Mar 5, 2025 |
| 4 | Insider transaction | Mar 4, 2025 | Mar 3, 2025 |
| 4 | Insider transaction | Mar 4, 2025 | Mar 3, 2025 |
| 4 | Insider transaction | Mar 4, 2025 | Mar 3, 2025 |
| 4 | Insider transaction | Mar 4, 2025 | Mar 3, 2025 |
| 424B5 | Prospectus supplement | Mar 4, 2025 | — |
| 8-K |
Current report
Material agreement, Agreement ended
|
Mar 4, 2025 | Mar 3, 2025 |
| S-8 | Employee stock plan registration | Mar 3, 2025 | — |
| 10-K | Annual report | Mar 3, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Jan 10, 2025 | Jan 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 16, 2024 | Dec 16, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2024 | Nov 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 18, 2024 | — |
| 4 | Insider transaction | Sep 30, 2024 | Sep 27, 2024 |
| 4 | Insider transaction | Sep 30, 2024 | Sep 27, 2024 |
| 4 | Insider transaction | Sep 17, 2024 | Sep 13, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Sep 17, 2024 | — |
| 424B5 | Prospectus supplement | Sep 13, 2024 | — |
| 8-K |
Current report
Material agreement
|
Sep 12, 2024 | Sep 11, 2024 |
| 424B5 | Prospectus supplement | Sep 10, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2024 | Sep 10, 2024 |
| S-8 | Employee stock plan registration | Aug 12, 2024 | — |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 15, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 20, 2024 | Jun 17, 2024 |
| DEFA14A | Additional proxy material | Jun 10, 2024 | — |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 17, 2024 |
| 8-K |
Current report
Material agreement
|
Apr 16, 2024 | Apr 10, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 1, 2024 | — |
| 4 | Insider transaction | Apr 1, 2024 | Mar 28, 2024 |
| S-8 | Employee stock plan registration | Feb 28, 2024 | — |
| 10-K | Annual report | Feb 27, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2024 | Feb 27, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 3 | Initial insider ownership | Feb 14, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| 4 | Insider transaction | Feb 7, 2024 | Feb 5, 2024 |
| SC 13G | Ownership over 5% (passive) | Jan 29, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 29, 2024 | — |
| 4 | Insider transaction | Jan 24, 2024 | Jan 22, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jan 24, 2024 | — |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Jan 19, 2024 | Jan 17, 2024 |
| 424B5 | Prospectus supplement | Jan 19, 2024 | — |
| 424B5 | Prospectus supplement | Jan 17, 2024 | — |
| 3 | Initial insider ownership | Jan 12, 2024 | Jan 3, 2024 |
| SC 13G | Ownership over 5% (passive) | Jan 10, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 8, 2024 | Jan 3, 2024 |
| 144 | Notice of proposed sale | Dec 18, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Dec 18, 2023 | Dec 15, 2023 |
| 144 | Notice of proposed sale | Dec 12, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Dec 8, 2023 | — |
| 144 | Notice of proposed sale | Dec 7, 2023 | — |
| 144 | Notice of proposed sale | Dec 1, 2023 | — |
| S-3ASR | Automatic shelf registration | Nov 30, 2023 | — |
| 144 | Notice of proposed sale | Nov 16, 2023 | — |
| 4 | Insider transaction | Nov 13, 2023 | Nov 10, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 3, 2023 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Nov 2, 2023 | Oct 29, 2023 |
| 4 | Insider transaction | Nov 1, 2023 | Oct 30, 2023 |
| 3 | Initial insider ownership | Nov 1, 2023 | Oct 30, 2023 |
| 4 | Insider transaction | Nov 1, 2023 | Oct 30, 2023 |
| 4 | Insider transaction | Nov 1, 2023 | Oct 30, 2023 |
| 3 | Initial insider ownership | Nov 1, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Oct 30, 2023 | Oct 29, 2023 |
| 4 | Insider transaction | Sep 25, 2023 | Sep 21, 2023 |
| 3 | Initial insider ownership | Sep 25, 2023 | Sep 21, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 25, 2023 | Sep 21, 2023 |
| 3 | Initial insider ownership | Sep 19, 2023 | Sep 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2023 | Sep 8, 2023 |
| S-8 | Employee stock plan registration | Aug 8, 2023 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.